This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April
Key Points
Chief Administrative and Accounting Officer Jonathan Gillis sold 69,835 shares of common stock for a total transaction value of approximately $2.09 million, with sales executed at a weighted average price of around $29.89 per share on April 27 and April 28, 2026.
The transaction reduced Gillis' direct common stock holdings by 27.8%, from 251,054 to 181,219 shares.
All shares sold were directly owned; no indirect entities or derivative securities were involved in this transaction.
- 10 stocks we like better than MapLight Therapeutics ›
MapLight Therapeutics (NASDAQ:MPLT) Chief Administrative and Accounting Officer Jonathan Gillis disclosed the direct sale of 69,835 shares of common stock in multiple open-market transactions on April 27 and April 28, 2026, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value | Context |
|---|---|---|
| Shares sold (direct) | 69,835 | Open-market shares sold (code "S") in this filing |
| Transaction value | ~$2.09 million | Based on SEC Form 4 weighted average purchase price ($29.89) |
| Post-transaction shares (direct) | 181,219 | Directly held shares after transaction completion |
| Post-transaction value (direct ownership) | ~$5.49 million | Based on April 28, 2026 market close ($30.31) |
Key questions
- How does this sale compare to Gillis' recent insider activity?
This transaction is the largest direct sale by Gillis in the past year, accounting for 27.8% of his pre-transaction direct common stock holdings and representing a step-up in sale size compared to the previous open-market sale of 3,590 shares on April 15, 2026. - Was this transaction part of a routine plan or discretionary selling?
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on Dec. 26, 2025, indicating the sales were pre-scheduled and part of routine liquidity management. - Were any indirect holdings or derivative securities involved?
No indirect entities or derivatives were transacted; all shares sold were directly owned common stock, with no change to indirect or option-based positions.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close April 28, 2026) | $30.31 |
| Market capitalization | $1.25 billion |
| Net income (TTM) | ($161.15 million) |
| Number of employees | 133 |
| Headquarters | Redwood City, CA |
| Industry | Biotechnology |
Company snapshot
- Develops clinical-stage therapeutics targeting central nervous system disorders, including schizophrenia, Alzheimer's disease psychosis, autism spectrum disorder, Parkinson's disease, and agitation-related conditions.
- Operates a research-driven business model focused on advancing proprietary drug candidates through clinical trials.
MapLight Therapeutics is a clinical-stage biotechnology company leveraging a proprietary platform to identify and modulate neural circuits linked to disease. With a diversified pipeline addressing multiple high-need central nervous system indications, the company seeks to create differentiated therapies for complex neuropsychiatric and neurodegenerative disorders. Its strategy emphasizes innovation in drug discovery and translational research to establish a competitive edge in the biopharmaceutical sector.
What this transaction means for investors
Gillis’ $2 million late-April transaction was part of a Rule 10b5-1 trading plan, a common tool that allows company insiders to transact shares on a predetermined basis, mitigating the appearance of insider trading. The stock had returned nearly 80% year over year as of April 28.
Wall Street sees strong potential for the company. In March, Canaccord initiated coverage of MapLight Therapeutics with a buy rating and a $35 price target. On April 7 and 8, TD Cowen and Needham weighed in, each initiating coverage of the stuck with a buy rating.
Analysts point to the company’s focus on novel central nervous system therapeutics as a differentiator for the treatment of schizophrenia, and point to the third-quarter release of phase 2 data for its lead asset, ML-007C-MA, which has the potential to reach blockbuster drug status by 2035.
Like many small-cap companies in the biopharma space, MapLight is currently unprofitable, and its performance could swing dramatically on positive (or negative) clinical trial results. Interested investors will want to keep an eye on its pipeline and clinical trial schedule.
Should you buy stock in MapLight Therapeutics right now?
Before you buy stock in MapLight Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and MapLight Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $496,473!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,216,605!*
Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 202% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 4, 2026.
Sarah Sidlow has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
